Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder. METHOD: The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRIs for treating adults with major depressive disorder. Trials were also required to assess improvement in depression severity at multiple time points. Additional data were collected on treatment response and all-cause and side effect-related discontinuation. All medication doses were transformed into imipramine-equivalent doses. The longitudinal data were analyzed with a mixed-regression model. Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder. RESULTS: Forty studies involving 10,039 participants were included. Longitudinal modeling (dose-by-time interaction=0.0007, 95% CI=0.0001-0.0013) and endpoint analysis (meta-regression: β=0.00053, 95% CI=0.00018-0.00088, z=2.98) demonstrated a small but statistically significant positive association between SSRI dose and efficacy. Higher doses of SSRIs were associated with an increased likelihood of dropouts due to side effects (meta-regression: β=0.00207, 95% CI=0.00071-0.00342, z=2.98) and decreased likelihood of all-cause dropout (meta-regression: β=-0.00093, 95% CI=-0.00165 to -0.00021, z=-2.54). CONCLUSIONS: Higher doses of SSRIs appear slightly more effective in major depressive disorder. This benefit appears to plateau at around 250 mg of imipramine equivalents (50 mg of fluoxetine). The slightly increased benefits of SSRIs at higher doses are somewhat offset by decreased tolerability at high doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 1×
“Six different SSRIs were studied in placebo-controlled trials with major depressive disorder: fluoxetine (k=9, n= 2386) (17, 21, 29, 31, 46, 47, 49, 51, 56), fluvoxamine (k=8, n=910)(18, 24, 27, 38, 39, 42, 45, 54), paroxetine (k=16, n=3424)(19, 20, 22, 23, 25, 26, 28, 30, 33, 34, 36, 44, 48, 52, 55), sertraline (k=3,…”
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Self-citationMeta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317
Self-citationNational trends in the treatment for depression from 1998 to 2007
Marcus, S. C., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.151 · Cited by 312
Bollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Entsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Wootton, R. E., Richmond, R. C., Stuijfzand, B. G., Lawn, R. B., Sallis, H. M., Taylor, G. M. J., Hemani, G., Jones, H. J., Zammit, S., Davey Smith, G., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291719002678 · Cited by 587
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322
Management of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“Dosage and duration of antidepressants Most studies and meta-analyses have found no benefit for antidepressant dose escalation versus staying on the minimum licensed dose, with an increased risk of side effects and discontinuation [32, 33], even if there is also evidence that higher doses may have superior efficacy [3…”
BackgroundWalter, H. J., Abright, A. R., Bukstein, O. G., Diamond, J., Keable, H., Ripperger-Suhler, J., & Rockhill, C. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.10.001 · Cited by 193
“177 Accordingly, if the 4-to 6-week assessments show minimal response, a trial of a second SSRI could be considered (although, in some situations, dose increase of the initial SSRI may be warranted).”
BackgroundPharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Self-citationOh, J., Jang, S., Kim, H., & Kim, J.-J. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2020.104171 · Cited by 124
Hieronymus, F., Nilsson, S., & Eriksson, E. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.104 · Cited by 100
Strawn, J. R., Mills, J. A., Sauley, B. A., & Welge, J. A. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.01.015 · Cited by 98
Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz003 · Cited by 70
“In line with this observation, drugs that inhibit the reuptake of 5-HT such as selective serotonin reuptake inhibitors (SSRIs) have repeatedly proven efficacious for the treatment of MDD in many but not all subjects (Jakubovski et al., 2016; Locher et al., 2017; Cipriani et al., 2018).”
BackgroundA randomized controlled trial of medication and cognitive-behavioral therapy for hypochondriasis
Fallon, B. A., Ahern, D. K., Pavlicova, M., Slavov, I., Skritskya, N., & Barsky, A. J. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16020189 · Cited by 65
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Self-citationBöge, K., Hahne, I., Bergmann, N., Wingenfeld, K., Zierhut, M., Thomas, N., Ta, T. M. T., Bajbouj, M., & Hahn, E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.008 · Cited by 44
Vaughn, S., Strawn, J., Poweleit, E., Sarangdhar, M., & Ramsey, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070615 · Cited by 40
“As increased SSRI plasma concentration is associated with increased activation [64], the implications include a decrease in tolerability secondary to activation.”
BackgroundCheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz062 · Cited by 38
Braun, C., Adams, A., Rink, L., Bschor, T., Kuhr, K., & Baethge, C. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13235 · Cited by 36
“Both meta-analyses, however, employed indirect comparisons, be it by analyzing different SSRI doses across studies, not within studies (5), or by choosing the response against placebo as a yardstick (6).”
BackgroundInfluentialBartova, L., Fugger, G., Dold, M., Swoboda, M. M. M., Zohar, J., Mendlewicz, J., Souery, D., Montgomery, S., Fabbri, C., Serretti, A., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.028 · Cited by 25
Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence
Cellini, L., De Donatis, D., Zernig, G., De Ronchi, D., Giupponi, G., Serretti, A., Xenia, H., Conca, A., & Florio, V. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000386 · Cited by 24
Safer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Toward a generalized developmental model of psychopathological liabilities and psychiatric disorders
Blanco, C., Wall, M. M., Hoertel, N., Krueger, R. F., & Olfson, M. (2023) · Psychological Medicine · doi:10.1017/s0033291721005468 · Cited by 10
Hahne, I., Zierhut, M., Bergmann, N., Hahn, E., Ta, T. M. T., Calvano, C., Bajbouj, M., & Böge, K. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae198 · Cited by 4
Metadata
- Authors
- Jakubovski, E., Varigonda, A. L., Freemantle, N., Taylor, M. J., & Bloch, M. H.
- Venue
- American Journal of Psychiatry
- Published
- 2016-02-01
- Volume
- 173
- Issue
- 2
- Pages
- 174-183
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2099328792
- Cited by
- 197
- References
- 14
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.